Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Dr. Reddy’s Laboratories (RDY) Stock Price
News stories about Dr. Reddy’s Laboratories (NYSE:RDY) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dr. Reddy’s Laboratories earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the company an impact score of 48.1617321296145 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Trending Stocks: Cott Corporation, (NYSE: COT), Dr. Reddy’s Laboratories Limited, (NYSE: RDY), Trex Company, Inc … – Stocks In The News (press release) (tradingnewsnow.com)
- Comprehensive Stock Analysis – Dr. Reddy’s Laboratories Limited, (NYSE: RDY) – Stock Watch (stocksnewstimes.com)
- Jefferies Group Weighs in on Dr. Reddy’s Laboratories Ltd’s FY2018 Earnings (RDY) (americanbankingnews.com)
- Endo International plc (ENDP) is at $5.96 per share and Dr. Reddy’s … – Stocks Gallery (stocksgallery.com)
- Stocks Midday Alert: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), Dr. Reddy’s Laboratories Limited (NYSE:RDY) – The Stock Street (press release) (thestreetpoint.com)
Shares of Dr. Reddy’s Laboratories (RDY) traded down $0.37 during midday trading on Tuesday, hitting $36.37. 7,152 shares of the stock traded hands, compared to its average volume of 324,501. Dr. Reddy’s Laboratories has a 1-year low of $29.83 and a 1-year high of $49.68. The firm has a market capitalization of $6,080.00, a price-to-earnings ratio of 35.68, a price-to-earnings-growth ratio of 10.75 and a beta of 0.41. The company has a current ratio of 1.46, a quick ratio of 1.08 and a debt-to-equity ratio of 0.20.
RDY has been the subject of a number of recent analyst reports. CLSA raised shares of Dr. Reddy’s Laboratories from an “underperform” rating to an “outperform” rating in a report on Thursday, August 31st. Jefferies Group LLC reaffirmed a “sell” rating and issued a $31.62 price objective on shares of Dr. Reddy’s Laboratories in a report on Sunday, September 3rd. BidaskClub cut shares of Dr. Reddy’s Laboratories from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Zacks Investment Research raised shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a report on Friday, July 14th. Finally, Morgan Stanley upgraded shares of Dr. Reddy’s Laboratories from an “equal weight” rating to an “overweight” rating in a research report on Thursday, September 21st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Dr. Reddy’s Laboratories has a consensus rating of “Hold” and a consensus target price of $30.51.
Dr. Reddy’s Laboratories Company Profile
Dr. Reddy’s Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics).
Receive News & Ratings for Dr. Reddy's Laboratories Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Reddy's Laboratories Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.